Protecting America’s Medical Supply Chains Act of 2026
Summary
What This Bill Does
The Protecting America's Medical Supply Chains Act adds a Defense Production Act policy statement that the Act's authorities should be used when appropriate to ensure medical materials essential to national defense. It expressly includes drugs, medical devices, and biological products used to diagnose, cure, mitigate, treat, or prevent disease, while directing attention to U.S. competitiveness, scientific leadership, allied cooperation, and innovation.
Within 180 days, the President must send specified congressional leaders and banking committees a strategy for using DPA title I, title III, and other authorities to secure essential medical materials. The strategy must analyze vulnerabilities, address diversification, discuss production, cost, and distribution effects, set a timeline for ending threatening exclusive foreign-government control of essential components, and explain risk mitigation for U.S. competitiveness and innovation. Annual progress reports continue until September 30, 2029. Reports are unclassified but may include classified annexes.
The bill separately allows the President to make payments to an eligible entity to improve supply-chain security after certifying to Congress at least 30 days beforehand that the payment is critical to national-defense requirements. The entity must be organized under U.S. law and produce critical components, critical technology, or products or raw materials relevant to supply-chain security.
Within 90 days, the President must define "supply chain" and "supply chain activities" by regulation. The definitions must reach organizations, people, activities, information, and resources involved in government product or service delivery, or critical infrastructure, and may include defense-specific variations. The bill authorizes payments but states no appropriation amount, recipient entitlement, mandatory award, domestic-content percentage, or prohibition on foreign inputs.
Who Benefits and How
Domestic producers of drugs, devices, biologics, critical components, technology, and raw materials become eligible for discretionary DPA payments and greater federal demand. Patients, military personnel, healthcare providers, and critical-infrastructure operators may face lower shortage risk. Congress gains recurring supply-chain visibility.
Who Bears the Burden and How
Federal agencies must develop the strategy, coordinate across departments, issue regulations, certify individual payments, and report annually. The DPA funding source and federal taxpayers bear payment costs. Applicants must prove domestic organization, eligible production, and national-defense importance. Foreign-controlled suppliers may lose business as the strategy diversifies vulnerable supply chains.
Key Provisions
- Expands DPA policy to essential medical materials.
- Includes drugs, devices, and biological products.
- Requires a presidential strategy within 180 days.
- Requires analysis of supply-chain vulnerabilities.
- Directs diversification measures for national defense.
- Requires a timeline addressing exclusive foreign-government control.
- Requires mitigation of competitiveness and innovation risks.
- Requires annual reports through September 2029.
- Allows classified annexes to public-form reports.
- Authorizes payments to eligible domestic entities.
- Requires congressional certification 30 days before payment.
- Limits eligibility to specified supply-chain production.
- Requires regulatory definitions within 90 days.
- Provides no stated appropriation amount.
- Creates no mandatory payment entitlement.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
Expands Defense Production Act policy and planning to medical materials essential to national defense, requires a medical supply-chain strategy and annual progress reports through September 2029, and authorizes certified payments to eligible domestic supply-chain producers under presidentially defined terms.
Key Policy Areas
Defense Production Act, Medical Supply Chains, Drug Security, Critical Infrastructure, National Defense Industrial Policy
Primary Purpose
Expands Defense Production Act policy and planning to medical materials essential to national defense, requires a medical supply-chain strategy and annual progress reports through September 2029, and authorizes certified payments to eligible domestic supply-chain producers under presidentially defined terms.
Policy Domains
Sections 2 and 3 DPA medical-material policy, essential-material scope, 180-day strategy, annual reports, domestic-entity payment authority, congressional certification, and 90-day definitions
Identified Gains
- Domestic medical-material manufacturers
- Domestic drug manufacturers
- Domestic medical-device manufacturers
- Domestic biological-product manufacturers
- Critical-component producers
- Critical-technology producers
- Patients dependent on essential medical supplies
- Military medical logistics programs
- Congressional defense-production overseers
Identified Costs
- Defense Production Act program staff
- Presidential supply-chain policy staff
- Federal taxpayers financing DPA payments
- Payment applicants documenting eligibility
- Foreign-controlled medical suppliers
- Federal agencies preparing annual reports
Legislative Progress
In CommitteeReferred to the House Committee on Financial Services.
Introduced in House
Ms. Salazar introduced the following bill; which was referred to …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Congressional defense-production overseers, Defense Production Act program staff, Department of Commerce
Positive-direction: Congressional defense-production overseers
Negative-direction: Defense Production Act program staff, Department of Commerce, Department of Defense, Department of Health and Human Services, Department of Homeland Security, Presidential regulatory staff, Presidential supply-chain policy staff
Domestic medical-device manufacturers, Domestic medical-material manufacturers, Foreign-controlled medical suppliers
Positive-direction: Domestic medical-device manufacturers, Domestic medical-material manufacturers, Patients dependent on essential medical supplies
Negative-direction: Foreign-controlled medical suppliers
Critical-component producers, Domestic raw-material producers, Foreign-organized supply-chain producers
Government product suppliers, Payment applicants documenting eligibility
Positive-direction: Government product suppliers
Negative-direction: Payment applicants documenting eligibility
Domestic biological-product manufacturers, Domestic drug manufacturers
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "patient"
- → Person relying on secure medical-material supplies
- "congress"
- → Specified congressional leaders and committees receiving submissions
- "producer"
- → Domestic entity producing eligible supply-chain goods
- "president"
- → President preparing the strategy, regulations, certifications, and payments
- "foreign_supplier"
- → Foreign-controlled source implicated by diversification planning
- "health_secretary"
- → HHS Secretary consulting on medical materials
Note: {'scope_ids': ['defense_medical_supply_chain_strategy_and_payments'], 'description': 'The bill creates policy, planning, and discretionary payment authority rather than a guaranteed procurement program; it states no funding amount, lets the President define supply-chain scope broadly, and balances diversification against competitiveness, scientific leadership, cooperation, and innovation.'}
Key Definitions
Terms defined in this bill
An entity organized under U.S. law that produces critical components, critical technology, or products or raw materials for supply-chain security.
Drugs, devices, biological products, and related materials used to diagnose, cure, mitigate, treat, or prevent disease when needed for national defense.
A presidential certification to Congress at least 30 days before payment that the payment is critical to national-defense requirements.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology